EVLO · Evelo Biosciences, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|
| Revenue | - | - | - | - | - |
| Cost of Revenue | - | - | - | - | - |
| Gross Profit | - | - | - | - | - |
| R&D | $78.55M | $83.64M | $69.62M | $63.13M | $9.13M |
| SG&A | $29.91M | $31.75M | $22.27M | $23.23M | $3.89M |
| Total Operating Expenses | $108.47M | $115.40M | $91.89M | $86.36M | $13.03M |
| D&A | $2.06M | $2.22M | $2.03M | $1.76M | $495.0K |
| Operating Income | ($108.47M) | ($115.40M) | ($91.89M) | ($86.36M) | ($13.03M) |
| Interest Expense | - | - | - | - | $300.0K |
| Income Tax | $930.0K | $428.0K | $409.0K | $0 | - |
| Net Income | ($114.53M) | ($122.18M) | ($93.67M) | ($85.47M) | ($13.33M) |
| EPS - Basic | ($26.20) | ($47.40) | - | - | - |
| EPS - Diluted | ($26.20) | ($47.40) | - | - | - |
Balance Sheet
| Line item | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|
| Cash & Equivalents | $47.94M | $68.44M | $68.86M | $77.83M | $93.10M |
| Accounts Receivable | - | - | - | - | - |
| Inventory | - | - | - | - | - |
| Accounts Payable | $1.76M | $1.60M | $1.44M | $620.0K | $1.52M |
| Current Assets | $51.57M | $71.03M | $70.98M | $81.01M | $151.62M |
| Total Assets | $64.44M | $87.87M | $90.64M | $90.92M | $159.87M |
| Current Liabilities | $12.39M | $17.36M | $19.83M | $9.74M | $9.23M |
| Long-term Debt | $43.61M | $46.56M | $30.05M | $19.63M | $12.30M |
| Total Liabilities | $69.43M | $79.20M | $60.15M | $30.72M | $22.92M |
| Stockholders' Equity | ($4.99M) | $8.67M | $30.48M | $60.20M | ($4.47M) |
| Retained Earnings | ($529.22M) | ($414.69M) | ($292.52M) | ($198.85M) | ($113.38M) |
Cash Flow
| Line item | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|
| Operating Cash Flow | ($101.23M) | ($96.72M) | ($73.06M) | ($71.98M) | ($12.31M) |
| Investing Cash Flow | ($622.0K) | ($1.48M) | ($1.31M) | $51.97M | $9.26M |
| Financing Cash Flow | $81.66M | $97.54M | $65.47M | $4.99M | $15.74M |
| CapEx | $622.0K | $1.52M | $1.32M | $3.03M | $1.25M |
| Free Cash Flow | ($101.86M) | ($98.24M) | ($74.38M) | ($75.01M) | ($13.56M) |
Ratios
| Metric | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|
| Profitability | |||||
| Gross margin | - | - | - | - | - |
| Operating margin | - | - | - | - | - |
| EBITDA margin | - | - | - | - | - |
| Net margin | - | - | - | - | - |
| Free cash flow margin | - | - | - | - | - |
| FCF / Net income | 0.89 | 0.80 | 0.79 | 0.88 | 1.02 |
| R&D / Revenue | - | - | - | - | - |
| SG&A / Revenue | - | - | - | - | - |
| Effective tax rate | - | - | - | - | - |
| Return on assets | -177.7% | -139.0% | -103.3% | -94.0% | -8.3% |
| Return on equity | 2294.2% | -1409.7% | -307.3% | -142.0% | 298.2% |
| Return on invested capital | -221.9% | -165.1% | -119.9% | -85.5% | - |
| Liquidity | |||||
| Current ratio | 4.16 | 4.09 | 3.58 | 8.31 | 16.42 |
| Quick ratio | 4.16 | 4.09 | 3.58 | 8.31 | 16.42 |
| Cash ratio | 3.87 | 3.94 | 3.47 | 7.99 | 10.08 |
| Leverage | |||||
| Debt / Equity | -8.74 | 5.37 | 0.99 | 0.33 | -2.75 |
| Debt / Assets | 0.68 | 0.53 | 0.33 | 0.22 | 0.08 |
| Debt / EBITDA | - | - | - | - | - |
| Interest coverage | - | - | - | - | -43.4x |
| Equity multiplier | -12.91 | 10.14 | 2.97 | 1.51 | -35.76 |
| Liabilities / Assets | 1.08 | 0.90 | 0.66 | 0.34 | 0.14 |
| Efficiency | |||||
| Asset turnover | - | - | - | - | - |
| Inventory turnover | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - |
| Valuation | |||||
| P / E | - | - | - | - | - |
| P / B | - | 553.0x | - | - | - |
| P / S | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - |
| Growth | |||||
| Revenue growth (YoY) | - | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - |
| Operating income growth (YoY) | 6.0% | -25.6% | -6.4% | -563.0% | - |
| Net income growth (YoY) | 6.3% | -30.4% | -9.6% | -541.1% | - |
| EPS growth (YoY) | 44.7% | - | - | - | - |
| EPS CAGR (3y) | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - |
| FCF growth (YoY) | -3.7% | -32.1% | 0.8% | -453.0% | - |
| FCF CAGR (5y) | - | - | - | - | - |
| Book value growth (YoY) | - | -71.6% | -49.4% | - | - |
Stability scores
Piotroski F-score
FY 2022 · 9-point quality
3/9
Weak
- ✗Net income positive
- ✗Operating cash flow positive
- ✗ROA improved YoY
- ✓Cash flow > net income
- ✓Long-term debt decreased
- ✓Current ratio improved
- ✗No share dilution
- -Gross margin improved
- -Asset turnover improved
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing Evelo Biosciences against the 5 most active filers in the same SIC group.